Extended-Release Oral Minoxidil Posts First Efficacy Win in Women With Hair Loss
Veradermics (NYSE: MANE) said its extended-release oral minoxidil tablet VDPHL01 showed clinically meaningful hair growth in women with female pattern hair loss in Phase 2 Study 207. In 22 women over 6 months, once-daily and twice-daily doses increased non-vellus hair counts by 22.7 and 23.3 hairs/cm², with no treatment-related serious adverse events. Enrollment for Study 306 continues; topline expected H1 2027.
How this was made
The 30-second read
Why it matters
A first positive female clinical signal for VDPHL01 is a meaningful de-risking step for Veradermics’ confirmatory pathway, but it remains Phase 2 open-label and therefore not definitive for FDA submission.
Market read
The announcement provides new efficacy and safety datapoints in women, which can re-rate the probability of success for the female pivotal program and drive near-term trading in MANE.
What to watch
Key next risk is whether the randomized, double-blind placebo-controlled Study 306 reproduces these signals; also, the article does not provide durability beyond six months or detailed adverse-event rates beyond no serious events.
Background
Female pattern hair loss has no FDA-approved prescription oral treatment; topical minoxidil is OTC and oral options are largely off-label with limited registration-grade evidence.
Ticker impact
Veradermics reported first positive female Phase 2 efficacy signal for extended-release oral minoxidil VDPHL01, with pre-market share gains.
Likely near-term positive bias for MANE on continued biotech momentum, with volatility around upcoming confirmatory trial milestones.
The article discloses new Phase 2 female-arm efficacy datapoints (hair counts and PROs) plus safety observations, and notes confirmatory Study 306 is already enrolling with topline expected in 1H 2027.
Market effects
Supports the oral minoxidil extended-release thesis in androgenetic alopecia, potentially improving sentiment for hair-loss drug development broadly.
Primarily US biotech sentiment given the NYSE-listed issuer and FDA-focused framing.
Could strengthen expectations for future regulatory discussions in the US and Europe if Study 306 confirms efficacy.
Counterpoint
Open-label, small-cohort Phase 2 data without a comparator can overstate efficacy; placebo and enrollment effects may inflate hair-count and PRO outcomes.
Key entities
- companyVeradermics
NYSE-listed developer of extended-release oral minoxidil VDPHL01 for female pattern hair loss.
- drug_candidateVDPHL01
Extended-release oral minoxidil tablet designed to sustain exposure for follicular sulfation and improve efficacy while targeting cardiac safety.
- clinical_trialStudy '207'
Ongoing 12-month Phase 2 open-label trial in 22 women; six-month female-arm results were reported.
- clinical_trialStudy '306'
Randomized, double-blind, placebo-controlled Phase 2/3 trial targeting more than 500 women; topline expected in 1H 2027.
